Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
doi:10.1016/j.exger.2024.112522
doi: 10.3389/fcell.2016.00016 Received 29 November 2015 Accepted 22 February 2016 Published 23 March 2016 Volume 4 - 2016 Edited by Gaetano Santulli, Columbia University in the City of New York, USA Reviewed by Yves Combarnous, Centre National de la Recherche Scientifique, France
It was shown that Latino/Hispanic patients treated with liraglutide achieved significant HbA1c reductions versus the comparators of glimepiride, placebo, and sitagliptin respectively
Hajra A, Safiriyu I, Balasubramanian P, et al
This innovation results in an elimination half-life of approximately 90 h (~4 days), supporting a once-weekly SC dosing regimen
US$ 20.76
US$ 25.25
US$ 24.57
US$ 29.31
US$ 20.51
US$ 29.83
US$ 20.12
US$ 26.05
